Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05404906 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Jun 2024 to Jun 2028
    • Study sites: 1 to 2
    • Study completion date: Jun 2025 to Jun 2030
    • Start date changed from estimate of Jun 2022 to Jun 25, 2022
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.
Trial Details
NCT Number NCT05404906
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions
(from sponsor)		 Acute Myeloid Leukemia (AML) in Remission
Related terms Leukemia, Myeloid, Acute
Enrollment 124 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov